WASHINGTON, DC--Research published yesterday suggests that we may be able to finally find a way to slow disease progression and provide preventative measures for the first time to individuals at risk of developing the 4th leading cause of death in the United States—chronic obstructive pulmonary disease (COPD).
In a bold proposal that challenges decades-old criteria, the new research analysis—published in the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation—proposes to expand the criteria by which smokers are diagnosed with COPD which affects an estimated 30 million individuals in the U.S. alone (15 million diagnosed, another 15 million estimated to be undiagnosed with the disease).
Using the new criteria proposed in the published article would enable treatment to be provided earlier to slow or halt disease progression before disability or irreversible lung structural changes occurs. This new proposal comes from the COPD Genetic Epidemiology (COPDGene) study—a 21-center study of 10,000 individuals supported by the National Institutes of Health and begun in 2007.
Washington, DC – November 1, 2019 - The COPD Foundation is pleased to announce the beginning of COPD Awareness Month. Held every November, Awareness Month is meant to help people understand the impact Chronic Obstructive Pulmonary Disease (COPD) has on people and the advances we are making every day.
The theme this year is #COPDTogether. Together, we can find innovative new ways to improve the lives of all people affected by COPD. Together, we can continue working towards a cure for this disease. Together, we can provide support and encouragement to all members of the COPD community. Together, there is nothing we can’t accomplish.
Throughout the month, we will be providing information about COPD on Twitter, Facebook and on our COPD360social interactive community. We invite all members of the COPD community to share their stories on social media as well. During the month, we will also be sharing a blog and video about the correlation between nontuberculous mycobacteria (NTM) lung disease and COPD. On Tuesday, November 19, we will be honoring five very special champions for COPD at our annual Gala in New York City.
WASHINGTON, DC, October 25, 2019— The COPD Foundation is pleased to announce that Ruth Tal-Singer, Ph.D., has joined the Foundation as a consultant in the role of Scientific Strategy Advisor. Ms. Tal-Singer is an internationally recognized expert and leader in the field of respiratory care. Her appointment became official as of October 21, 2019.
"We are so very excited that Ruth is joining the team. Ruth's deep expertise and commitment to the COPD community is so very impactful,” said Corinne Costa Davis, Chief Executive Officer of the COPD Foundation.
Prior to joining the COPD Foundation, Ms. Tal-Singer was Vice President of Medical Innovation (Galaxy) R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals. During her career with GSK, she led many projects that resulted in new and innovative treatments for COPD.
Washington, DC—October 21, 2019 - The COPD Foundation is pleased to announce that we have launched a new version of our popular Pocket Consultant Guide (PCG) mobile app featuring a track for patients and caregivers. The PCG was originally designed as a convenient reference card for healthcare providers. The mobile version was launched in 2013 and updated in 2018. Immediately after the updated app was launched, our team began thinking of ways to improve the patient experience through a mobile app.
"Since 2007 the COPD Foundation has distributed more than 800,000 pocket consultant cards to providers around the country in hope of improving COPD care. Several years ago, the Foundation updated our free app providing a more interactive service including inhaler videos. We believe the launch of the newest version represents another important step to improving care. This new version includes a patient track with an interactive daily action plan, activity monitoring, and exercise videos. Together we can make a difference!" – Dr. Byron Thomashow, Chief Medical Officer, COPD Foundation
The newest version of the app, now available on the App Store and Google Play, has several exciting new features, including the introduction of a patient and caregiver track designed to improve disease management and communication with a patient’s healthcare team. Some of the features of the patient track include:
NTM lung disease is a serious, often misdiagnosed condition that can cause severe, even permanent damage to the lungs.
WASHINGTON, D.C. - February 25, 2019 - In recognition of Rare Disease Day, the COPD Foundation will host a Facebook discussion about nontuberculous mycobacterial (NTM) lung disease on Thursday, February 28, 2019, at 1 p.m. ET. The event aims to raise awareness about this serious and often overlooked condition.
Entitled “Constant Cough, Fatigue & Shortness of Breath? Expert Reveals NTM Lung Disease as a Potential Cause,” this event will feature Dr. Doreen Addrizzo-Harris, pulmonologist and professor of medicine at NYU Langone Health, and a patient living with NTM lung disease. Together they will discuss the signs, symptoms and risk factors of NTM lung disease and how to get tested. They will also explore the impact NTM lung disease has on a person’s daily life.
NTM lung disease is a serious condition characterized by constant coughing, feeling tired and being short of breath. If ignored, these symptoms can worsen and permanent damage to the lungs can occur. While we all come into contact with NTM bacteria in our daily lives, NTM lung disease disproportionally affects people with pre-existing lung conditions including chronic obstructive pulmonary disease (COPD), bronchiectasis and asthma. NTM lung disease is often misdiagnosed or overlooked because the symptoms of NTM lung disease are very similar to the symptoms experienced by people with these other lung conditions.
Study shows individuals with COPD-CAP often require weeks to recover, resulting in missed work and participation in usual activities.
Washington, DC – February 4, 2019 – According to a new study posted online in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation and conducted by the COPD Foundation in collaboration with and funded by Pfizer Inc., community-acquired pneumonia (CAP), which carries a high morbidity and economic burden worldwide, is even more physically and economically devastating to the vulnerable population of individuals with chronic obstructive pulmonary disease (COPD). CAP is a common but serious lung infection that can be caused by bacterial or viral pathogens including Streptococcus pneumoniae, influenza or rhinovirus.
COPD across America – How is your state is doing?
WASHINGTON, D.C. – November 30, 2018 – The COPD Foundation is pleased to announce the results of a landmark effort that examines the burden of COPD across America. The “COPD in the United States” project looks at COPD at the state level, identifying differences across states, regions and data points, to inform public health and policy decision-making.
COPD affects an estimated 30 million Americans but, up until now, little has been known about how one state compares to another. With the addition in 2011 of a COPD question to the Centers for Disease Control and Prevention’s Behavioral Risk Factor Surveillance System (BRFSS), the nation’s largest public health survey, more actionable information has been collected. State level data also exists to highlight the healthcare services individuals with COPD use, other conditions people with COPD may have and how different groups of people with COPD are affected.
Just collecting data isn’t enough, though, as it often sits in fragmented databases, is not analyzed or available for advocates, public health and policy decision-makers. With this project, the COPD Foundation aims to change that.
YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US
DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year. COPD is the third leading cause of death and the fourth leading cause of hospital readmissions in the US, affecting approximately 16 million Americans.
(November 2, 2018) - WASHINGTON, D.C.
A group of patient and physician groups react to the final rule on Durable Medical Equipment (DME) and its application to supplemental oxygen:
While our organizations appreciate that members of Congress and the Centers for Medicare and Medicaid Services (CMS) recognize the numerous problems associated with patient access to oxygen in general and liquid oxygen systems, we believe that CMS’s decision today will not ultimately solve the problems facing patients who require supplemental oxygen. More link to https://www.lung.org/about-us/media/press-releases/patient-and-physician-groups-cms.html.
COPD Pocket Consultant Guide App now available for both iOS and Android
WASHINGTON, D.C. - November 5, 2018 –The COPD Foundation is excited to announce the launch of the COPD Pocket Consultant Guide (PCG) app for healthcare providers. The app, designed to support the treatment and management of COPD, is now available for both iOS and Android. To download the new COPD PCG app, click here.
Key features of the COPD PCG app include an updated therapy chart including the latest medications for COPD, inhaler instruction videos, depression and anxiety screeners, links to COPD Foundation resources and more.
Additional features, such as the Fletcher-Peto Impact of Smoking graph and lung volume reduction options, are included in the app as well as links to PRAXIS (the COPD Foundation’s online hub for healthcare providers), the Journal of the COPD Foundation and the National Heart, Lung and Blood Institute’s COPD National Action Plan.
WASHINGTON, D.C. - November 1, 2018 - The COPD Foundation is excited to celebrate COPD Awareness Month, an internationally recognized event held annually in November to enhance awareness of chronic obstructive pulmonary disease (COPD).
The COPD Foundation’s theme this year is “Hope and Inspiration,” which highlights the organization’s efforts to connect with COPD patients and remind them that COPD does not define them. It also aims to raise public awareness about the disease and showcase the many tools available to patients on their journey while encouraging them and their loved ones to take control of their COPD by learning more about their disease.
A number of activities have been designed to recognize patients, caregivers, friends, family members and healthcare providers impacted by COPD. These include:
Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options
BRIDGEWATER, N.J., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. ARIKAYCE is the first and only therapy approved in the U.S. specifically for patients with MAC lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality.
ARIKAYCE is the first product approved via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs.
“Today’s approval is a momentous occasion for all of us living with and advocating for people with MAC lung disease,” said Philip Leitman, President of Nontuberculous Mycobacteria Info & Research (NTMir). “ARIKAYCE provides a much-needed treatment for patients with this chronic and life-threatening disease who have not responded to the current standard of care. Many of these patients have been suffering for years and face significant challenges in their day-to-day lives, and we are excited to finally have an approved treatment for them.”